Biopharmaceutical Manufacturing, Upstream, Downstream processing news

Headlines

Germany grants BioNTech, CureVac $745m to advance Covid-19 vaccine work

To accelerate Covid-19 vaccine development, as well as upscale domestic manufacturing capabilities, the German government has announced a €750m (US$890m) fund to support the vaccine programs of three German developers, BioNTech, CureVac and IDT Biologika.

BioNTech acquires German manufacturing site to boost COVID-19 vaccine production

BioNTech will acquire Novartis’ GMP certified manufacturing facility in Marburg, Germany: with the site set to become one of the largest mRNA manufacturing plants in Europe.

Content provided by Yourway

Staying Ahead of COVID-19

The pandemic remains a globally disruptive entity that can impede efficacy of clinical trials. Choosing the right partner helps you concentrate on obtaining optimal results from at-home populations.

Epilepsy gene therapy candidate moves closer to clinical study phase

Gene therapy developer, CombiGene, and CDMO, Cobra Biologics, have signed off on a deal to secure Good Manufacturing Practice (GMP) production of two essential plasmids needed for the manufacture of CombiGene's gene therapy, CG01.